Scott S. Tykodi, MD, PhD

Physician
Seattle Cancer Care Alliance
Associate Professor, Division of Medical Oncology
UW Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Specialty:
Medical Oncology
“I believe patient education is a critical part of cancer care. Knowledge is power.”
— Dr. Tykodi
What's the focus of your work?

I’m a medical oncologist who treats patients with kidney cancer and melanoma. I’m particularly interested in the application of immune therapies to treat cancer. At SCCA, we aim to give you access to promising new treatments like these by offering you the option to participate in clinical trials. We want to present these opportunities to you right away, instead of having you wait. In the past, it could take days for newly diagnosed patients to obtain opinions from multiple specialists. Now we’re hopeful you can get all the information you need in a single visit to the Kidney Cancer Multidisciplinary Clinic or the Multidisciplinary Skin Oncology Clinic to begin making informed decisions about your care. After helping to design your initial treatment plan, I continue working closely with your other specialists to provide coordinated care throughout your time as a patient.

Tykodi_Secondary.jpg
What’s your approach to my care?

My goal is to keep you in control of your cancer journey. I believe patient education is a critical part of cancer care. Knowledge is power. What I love about working at SCCA is our multidisciplinary clinic. You’re anxious to be seen as quickly as possible. By having specialists work together, we’re accelerating timelines. In a single appointment, you’re evaluated by me or another medical oncologist, a urologist and a radiation oncologist. Receiving opinions from three specialty providers in real time is a great advantage for you and your referring physician, because a comprehensive treatment plan is laid out very quickly. With this streamlined approach, we hope you’ll know of every available treatment option from your very first visit.

Provider background

Specialty: Medical Oncology

Kidney cancer and melanoma

I am involved in the clinical application and translational study of natural or induced T-cell immunotherapy targeting renal cell carcinoma, kidney cancer and melanoma for SCCA clinical trials. In addition to working in the Clinical Research Division of Fred Hutch, I am also an associate professor at the UW School of Medicine.

Diseases treated

Education, experience and certifications
Medical Degree
Washington University School of Medicine
Residency
Barnes Jewish Hospital, Internal Medicine
Fellowship
University of Washington, Medical Oncology and Hematology-Oncology
Board Certification
Medical Oncology, 2003, 2013, American Board of Internal Medicine
Languages
English

Stories

Kidney cancer: Multidisciplinary clinic helps navigate changing treatment landscape
Kidney cancer: Multidisciplinary clinic helps navigate changing treatment landscape

Treatment for metastatic kidney cancer is evolving rapidly, as providers move away from performing upfront cytoreductive surgery and navigate a growing number of new therapies and combined drug regimens. SCCA’s Kidney Cancer Multispecialty Clinic (KCMC) offers multidisciplinary consultations and care to help community oncologists and their patients understand and access the latest treatment options. 

Research

Clinical trials

We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.

Study ID:
NCT04704219
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) (KEYNOTE-B61)
Complete title
A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)
Study ID:
Complete title
Specimen Collection in Patients with Renal Cell Carcinoma to Assess Tissue Correlates of Therapeutics: COSMIC 313 Population
Study ID:
NCT04540705
A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread (PIVOT IO 011)
Complete title
A Phase 1/2 Study to Evaluate the Triplet Combination of NKTR-214 plus Nivolumab and Axitinib and the Doublet Combination of Nivolumab and Axitinib in Participants with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (mRCC) (PIVOT IO 011)

Publications

Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.

Your care team

At SCCA, you receive care from a team of providers with extensive experience in your disease. Your team includes doctors, a team coordinator, a registered nurse, an advanced practice provider and others, based on your needs. You also have access to experts like nutritionists, social workers, acupuncturists, psychiatrists and more who specialize in supporting people with cancer or blood disorders.
Registered nurse (RN)
Registered nurse (RN)
Your nurse manages your care alongside your physician and assists with care procedures and treatments.
Team coordinator (TC)
Team coordinator (TC)
Your team coordinator works closely with you and your physician and serves as your scheduler.

Insurance

SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.

For providers